Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

Leonard, John P.; LaCasce, Ann S.; Smith, Mitchell R.; Noy, Ariela; Chirieac, Lucian R.; Rodig, Scott J.; Yu, Jian Q.; Vallabhajosula, Shankar; Schoder, Heiko; English, Patricia; Neuberg, Donna S.; Martin, Peter; Millenson, Michael M.; Ely, Scott A.; Courtney, Rachel; Shaik, Naveed; Wilner, Keith D.; Randolph, Sophia; Van den Abbeele, Annick D.; Chen-Kiang, Selina Y.; Yap, Jeffrey T.; Shapiro, Geoffrey I.

doi:10.1182/blood-2011-10-388298

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

Mantle cell lymphoma (MCL) carries an unfavorable prognosis and requires new treatment strategies. The associated t(11:14) translocation results in enhanced cyclin D1 expression and cyclin D1–dependent kinase activity to promote cell-cycle progression. A pharmacodynamic study of the selective CDK…